43392 Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices 

SUPPLEMENTARY INFORMATION: When 

submitting comments or requesting 

information, please include the 

information request collection title for 

reference, in compliance with Section 

3506(c)(2)(A) of the Paperwork 

Reduction Act of 1995. 

Information Collection Request Title: 

Poison Help General Population Survey 

OMB Number 0915–0343, 

Reinstatement. 

Abstract: HRSA is requesting 

approval by OMB for reinstatement with 

change of a previously approved 

collection of information (OMB control 

number 0915–0343). Annually, poison 

control centers (PCCs) in the U.S. 

manage approximately 2.8 million calls, 

providing ready and direct access to 

vital public health emergency 

information and response. In 2001, the 

Poison Help line, a single, national tollfree phone number (800–222–1222) was 

established to ensure universal access to 

PCC services, 24 hours a day, 7 days a 

week. The Poison Help campaign is the 

only national media effort to promote 

awareness and use of the national tollfree phone number. 

The Poison Help campaign aims to 

reach a wide audience, as individuals of 

all ages are at risk for poisoning and 

may need to access PCC services. The 

‘‘Poison Help General Population 

Survey’’ is a 10-minute telephone 

survey designed to assess the 

campaign’s impact among 2,000 

households in the United States. The 

survey is conducted with an adult 

household member and addresses topics 

related to the types of individuals or 

organizations to contact for information, 

advice, and treatment related to a 

poisoning. 

Need and Proposed Use of the 

Information: Survey results will be used 

to guide future communication, 

education, and outreach efforts and will 

allow the tracking of longitudinal data 

from near-identical prior surveys 

conducted in 2008 and 2011. The 

survey has been updated to include 

questions regarding one of the Secretary 

of HHS’ priority areas, addressing the 

opioid crisis, and to definitively 

ascertain respondents’ knowledge of the 

Poison Help Line and phone usage. 

Likely Respondents: This study 

includes two respondent groups, 

individuals and households with an 

adult member 18 years and older. 

Burden Statement: Burden in this 

context means the time expended by 

persons to generate, maintain, retain, 

disclose, or provide the information 

requested. This includes the time 

needed to review instructions; to 

develop, acquire, install and utilize 

technology and systems for the purpose 

of collecting, validating and verifying 

information, processing and 

maintaining information, and disclosing 

and providing information; to train 

personnel and to be able to respond to 

a collection of information; to search 

data sources; to complete and review 

the collection of information; and to 

transmit or otherwise disclose the 

information. The total annual burden 

hours estimated for this ICR are 

summarized in the table below. 

TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS

Instrument Number of 

respondents 

Responses per 

respondent 

Total 

responses 

Hours per 

response 

Total burden 

hours 

Survey Respondents ........................................................ 2000 1 2000 .166 332 

Screened households ...................................................... 2600 1 2600 .016 41.6 

Total .......................................................................... 4600 ............................ 4600 ........................ 374 

Amy McNulty. 

Acting Director, Division of the Executive 

Secretariat. 

[FR Doc. 2017–19608 Filed 9–14–17; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: Government owned 

intellectual property covering imaging 

agents with improved renal clearance 

available for licensing and 

commercialization. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

patent applications listed below may be 

obtained by emailing the indicated 

licensing contact at the National Heart, 

Lung, and Blood, Office of Technology 

Transfer and Development Office of 

Technology Transfer, 31 Center Drive, 

Room 4A29, MSC2479, Bethesda, MD 

20892–2479; telephone: 301–402–5579. 

A signed Confidential Disclosure 

Agreement may be required to receive 

copies of the patent applications. 

SUPPLEMENTARY INFORMATION: The 

inventions listed below are owned by an 

agency of the U.S. Government and are 

available for licensing in the U.S. in 

accordance with 35 U.S.C. 209 and 37 

CFR part 404 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. A description of the 

technology available for licensing 

follows. 

Methods of Using Inhibitors To 

Enhance Therapeutic Uses of 

Endocannabinoids 

Description of Technology: The 

invention pertains to methods of using 

compounds that inhibit fatty acid amide 

hydrolase (FAAH) enzymes that are 

responsible for the degradation of 

oleamide and anandamide. Inhibition of 

degradation can be used as treatment 

modality for hypertension and for sleep 

disorders. The issued patent lists 

potentially useful compounds, one such 

useful compound in particular is 


mstockstill on DSK30JT082PROD with NOTICESEN15SE.001</GPH>
Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices 43393 

Potential Commercial Applications: 

• Therapeutics for hypertension 

• Therapeutics for anxiety disorders 

• Therapeutics for sleep disorders 

Development Stage: 

• In vivo data available 

Inventors: George Kunos and 

Alexandros Makriyannis (both of 

NIAAA) 

Intellectual Property: HHS Reference 

No. E–211–2006/0–US–06. 

• U.S. Patent 8,293,724 filed April 6, 

2010, issued October 23, 2012. 

Licensing Contact: Michael 

Shmilovich, Esq, CLP; 301–435–5019; 

shmilovm@nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Environmental 

Health Sciences seeks statements of 

capability or interest from parties 

interested in collaborative research to 

further develop and evaluate, please 

contact Peg Koelble, Office of 

Technology Transfer, National Heart, 

Lung and Blood Institute, koelblep@

nhlbi.nih.gov, 301–594–4095. 

Dated: September 7, 2017. 

Michael Shmilovich, 

Senior Licensing and Patenting Manager, 

National Heart, Lung, and Blood Institute, 

Office of Technology Transfer and 

Development. 

[FR Doc. 2017–19590 Filed 9–14–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Chris Kornak, 240–627–3705, chris.

kornak@nih.gov. Licensing information 

and copies of the U.S. patent 

applications listed below may be 

obtained by communicating with the 

indicated licensing contact at the 

Technology Transfer and Intellectual 

Property Office (TTIPO), 5601 Fishers 

Lane, Suite 6D, MSC 9804, Rockville, 

MD 20892, tel: 301–496–2644, fax: 240– 

627–3117. A signed Confidential 

Disclosure Agreement will be required 

to receive copies of unpublished patent 

applications. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

Recombinant HIV-1 Envelope Proteins 

and Their Use 

Description of Technology: Millions of 

people are infected with HIV-1 

worldwide. In the U.S., there are about 

30,000 new cases of HIV infection 

reported annually. Currently, there are 

effective, anti-retroviral therapeutics 

available to treat or prevent HIV 

infection. However, available antiretroviral therapeutics require life-long 

administration. 

During infection, proteases of the host 

cell cleave gp160 into gp120 and gp41. 

Gp41 is an integral membrane protein, 

while gp120 protrudes from the mature 

virus. Together gp120 and gp41 

aggregate as trimers that make up the 

HIV-1 envelope (‘‘Env’’) spike, which is 

a target for neutralizing antibodies. 

NIAID researchers have constructed a 

recombinant HIV-1 trimer immunogen. 

In particular, the recombinant gp120 

protein in the trimer is stabilized in a 

closed conformation, preventing it from 

binding to CD4. The advantage of the 

closed conformation is that it can 

stabilize the epitopes that bind to 

broadly neutralizing antibodies, 

minimize the binding of gp120 with 

weakly or non-neutralizing antibodies, 

and prevent conformational changes 

induced by CD4 as well as immunogen 

sequestration by CD4 in vivo. Research 

has also indicated that recombinant Env 

ectodomain trimers can induce higher 

neutralizing antibody titers than wild 

type Env trimers in animal models. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• HIV-1 immunogen 

• New methods for isolating broadly 

neutralizing antibodies 

Competitive Advantages: 

• A new strategy in inducing immune 

response against HIV-1 

Development Stage: 

• Pre-Clinical; Proof-of-concept 

studies in nonhuman primate 

models 

Inventors: 

Paolo Lusso, NIAID, NIH 

Peng Zhang, NIAID, NIH 

Publications: Pending. 

Intellectual Property: HHS Reference 

No. E–102–2016/0—PCT Application 

No. PCT/US2017/021573 filed on 03/09/ 

2017. 

Licensing Contact: Chris Kornak, 240– 

627–3705, chris.kornak@nih.gov. 

Collaborative Research Opportunity: 

The Technology Transfer and 

Intellectual Property Office (TTIPO) is 

seeking parties interested in 

collaborative research to further develop 

the technology. In particular, NIAID is 

interested in partnerships utilizing 

vector vaccine platforms for expressing 

these immunogens. 

However, NIAID is willing to discuss 

other applications of this technology. 

For collaboration opportunities, please 

contact Chris Kornak, 240–627–3705, 

chris.kornak@nih.gov. 

Dated: September 7, 2017. 

Suzanne Frisbie, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2017–19591 Filed 9–14–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel; Chemical 

Senses Fellowship Review. 

Date: October 11, 2017. 

Time: 12:30 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health. 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Sheo Singh, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

6001 Executive Blvd., Room 8351, Bethesda, 

MD 20892, 301–496–8683, singhs@

nidcd.nih.gov. 

mstockstill on DSK30JT082PROD with NOTICES